AstraZeneca: Ovarian Neoplasms trials

The registry lists 70 Ovarian Neoplasms studies with AstraZeneca as lead sponsor. 8 are open to participants now and 19 have results posted.

Phase 1 23Phase 2 20Phase 3 11Phase 4 2No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerRecruitingNCT07816666Phase 3
• Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT07402915Phase 1
• DESTINY-PANTUMOUR04RecruitingNCT07124000
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
• Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingNCT05797168Phase 1/2
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
• A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
• Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results posted
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsActive, not recruitingNCT03737643Phase 3Results posted
• Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsCompletedNCT03402841Phase 3Results posted
• A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.CompletedNCT03106987Phase 3Results posted
• Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusCompletedNCT02983799Phase 2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results posted
• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
• To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerCompletedNCT02476968Phase 4Results posted
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsCompletedNCT02282020Phase 3Results posted
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive, not recruitingNCT01874353Phase 3Results posted
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active, not recruitingNCT01844986Phase 3Results posted
• A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid TumorsCompletedNCT01248949Phase 1Results posted
• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerActive, not recruitingNCT01081951Phase 2Results posted
• Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerCompletedNCT00753545Phase 2Results posted
• Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerCompletedNCT00679783Phase 2Results posted
• Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerCompletedNCT00628251Phase 2Results posted
• AZD0530 Phase II Study in Patients With Advanced Ovarian CancerCompletedNCT00610714Phase 2Results posted
• Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerCompletedNCT00494442Phase 2Results posted
• Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of HistologyActive, not recruitingNCT07167433
• A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian CancerWithdrawnNCT07060365Phase 1/2
• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
• Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World SettingCompletedNCT06324734
• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingNCT06188520Phase 1/2
• A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian FederationCompletedNCT05918042
• A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerCompletedNCT05775549
• A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
• D9319C00001- 1L OC Mono Global RCTActive, not recruitingNCT04884360Phase 3
• Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian CancerActive, not recruitingNCT04830709
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsCompletedNCT04560452
• 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926
• Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKCompletedNCT04532645
• An INternational Frontline Ovarian Cancer Real World Management StudyCompletedNCT04460768
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
• A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
• Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer PatientsCompletedNCT04222465
• A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
• Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedNCT03534453Phase 3
• Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)CompletedNCT03505307
• Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid TumorsCompletedNCT03490669Phase 1
• Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in IndiaCompletedNCT03471572
• Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCACompletedNCT03229122
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
• China Ovarian Cancer BRCA Testing StudyTerminatedNCT03203993
• Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf RegionCompletedNCT03082976
• Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Approved for marketingNCT03079687
• Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in JapanNo longer availableNCT03063710
• FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic StudyCompletedNCT02984423
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.CompletedNCT02610075Phase 1
• C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationCompletedNCT02503436
• Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
• Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
• Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsActive, not recruitingNCT02264678Phase 1
• OSCA - Olaparib Standard of CAre StudyCompletedNCT02262273
• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor TumorsCompletedNCT02144051Phase 1
• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedNCT01226316Phase 1
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelCompletedNCT00516724Phase 1
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)CompletedNCT00516373Phase 1
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00014690Phase 2